Improving the design of pivotal clinical trials.
Authors: Prasad VK PMID: 30969951 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 12, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Pressing the restart button as a new postgraduate from fellowship: year no. 1.
Authors: Humeniuk MS PMID: 30969952 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 12, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Advances in off-the-shelf CAR T-cell therapy.
Authors: Benjamin R PMID: 30969953 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 12, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Diagnosis and treatment of cold agglutinin disease.
Authors: Broome CM PMID: 30969954 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - April 12, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Treatment of relapsed/refractory acute lymphoblastic leukemia.
Authors: Paul S, Rausch CR, Nasnas PE, Kantarjian H, Jabbour EJ Abstract Patients with relapsed or refractory acute lymphoblastic leukemia (R/R ALL) have dismal outcomes, with survival of less than 6 months, and treatment options in the salvage setting have been limited to conventional cytotoxic chemotherapy with minimal activity. Advances in the development of novel targeted therapies have significantly improved outcomes in R/R ALL. Blinatumomab, inotuzumab ozogamicin, and chimeric antigen receptor (CAR) T-cell therapy constitute new treatment modalities that are challenging the historical regimens and paving a ne...
Source: Clinical Advances in Hematology and Oncology - April 12, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Update on perioperative systemic therapy for urothelial carcinoma.
Authors: Rouvinov K, Plimack ER, Zibelman M, Ghatalia P, Geynisman DM Abstract Level 1 evidence supports cisplatin-based neoadjuvant chemotherapy (NAC) in muscle-invasive urothelial bladder cancer (MIUBC). Recent data from small prospective trials with neoadjuvant immune checkpoint inhibitors are encouraging, but long-term follow-up is required. Randomized trials have failed to accrue a sufficient number of patients and have not demonstrated a survival benefit with adjuvant chemotherapy in MIUBC, but for those with high-risk features at surgery, adjuvant cisplatin-based therapy is appropriate. In upper tract urothe...
Source: Clinical Advances in Hematology and Oncology - April 12, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The use of multiparametric MRI in diagnosis and active surveillance of prostate cancer.
Authors: Polascik TJ PMID: 30843887 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - March 9, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

CAR T-cell therapy against B-cell maturation antigen in multiple myeloma.
Authors: Cohen AD PMID: 30843888 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - March 9, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Opportunities for using big data to advance cancer care.
Authors: Meropol NJ PMID: 30843889 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - March 9, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Management of adults with Burkitt lymphoma.
Authors: Gastwirt JP, Roschewski M Abstract Burkitt lymphoma (BL) is a highly aggressive B-cell non-Hodgkin lymphoma characterized by marked tumor proliferation resulting from translocation of the MYC oncogene. Distinct clinical variants include endemic, sporadic, and immunodeficiency-associated cases. All variants are characterized by rapidly dividing tumor masses that quickly disseminate to extranodal sites, including the bone marrow and central nervous system (CNS). Although common in children, BL is rare in adults, mandating a high index of clinical suspicion for timely diagnosis. Prompt recognition and initiat...
Source: Clinical Advances in Hematology and Oncology - March 9, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Contemporary management of the axilla in breast cancer.
Authors: Nurudeen S, Hunt KK Abstract The care of patients with breast cancer in the modern era involves a multimodal approach to treating locoregional and distant disease. Recent studies have demonstrated that the extent of surgical intervention in both the breast and axilla can be minimized through a personalized approach based on breast cancer stage, subtype, and planned adjuvant therapies. The older approach focused on complete removal of the axillary contents for appropriate staging and to determine the need for adjuvant systemic therapy and radiation. This approach has been replaced by sentinel lymph node bio...
Source: Clinical Advances in Hematology and Oncology - March 9, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Diagnosing or ruling out polycythemia vera in patients with erythrocytosis.
Authors: Prchal JT PMID: 30843892 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - March 9, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Choosing and managing a career as a community practitioner.
Authors: Regenbogen T PMID: 30843893 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - March 9, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Zanubrutinib: a novel BTK inhibitor in chronic lymphocytic leukemia and non-Hodgkin lymphoma.
Authors: Tam CS PMID: 30843894 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - March 9, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The current role of intralesional therapy in advanced melanoma.
Authors: Andtbacka RHI PMID: 30843895 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - March 9, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Moving from academia to industry in the field of oncology.
Authors: Soria JC PMID: 30843896 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - March 9, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

A new target in CTCL: treating the skin, blood, and lymph nodes.
Authors: Horwitz SM PMID: 30843897 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - March 9, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Adjuvant therapy in high-risk prostate cancer.
Authors: Shevach J, Chaudhuri P, Morgans AK Abstract Although the prognosis in patients with localized prostate cancer is positive overall, high-risk localized disease is responsible for significant cancer-related morbidity and mortality following local treatment failure. Despite recent medical advances in advanced prostate cancer, the role of systemic adjuvant therapy has remained relatively stagnant over the last few decades for patients with high-risk disease, consisting of only androgen deprivation therapy. Novel methods of risk stratification, however, based on traditional clinicopathologic features combined w...
Source: Clinical Advances in Hematology and Oncology - March 9, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Adjuvant treatment of surgically resectable pancreatic ductal adenocarcinoma.
Authors: Tesfaye AA, Philip PA Abstract Pancreatic ductal adenocarcinoma (PDAC) is the third-leading cause of cancer-related mortality in the United States. Surgical resection of early and localized disease provides the only chance for a cure; however, the majority of patients who have PDAC present with advanced disease that cannot be removed surgically. In the minority of patients who undergo surgical resection, there is a high rate of disease recurrence that eventually leads to death. The use of systemic therapy improves the outcome of patients who undergo surgery by targeting early micrometastatic disease. This ...
Source: Clinical Advances in Hematology and Oncology - March 9, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights from the 2018 San Antonio Breast Cancer Symposium.
Authors: PMID: 30845109 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - March 9, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Managing oncology drug costs in a constrained environment.
Authors: Clark P PMID: 30845110 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - March 9, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The future of combination treatment with checkpoint inhibitors in melanoma.
Authors: Sullivan RJ PMID: 30845111 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - March 9, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

When can tyrosine kinase inhibitors be discontinued in patients with chronic myeloid leukemia?
Authors: Mahon FX PMID: 30845112 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - March 9, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Balancing the risks and benefits of extended adjuvant endocrine therapy.
Authors: Jhaveri KL PMID: 30845113 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - March 9, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Biomarkers for immune therapy in gastrointestinal cancers.
Authors: Weinberg BA, Hameed R, Marshall JL Abstract Immunotherapy with checkpoint blockade of pro-grammed death 1 (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) has substantially increased the number of anticancer agents in our arsenal. However, these therapies are not effective in all cancer types, benefitting only a subset of patients with susceptible, immunogenic cancers. This problem is especially significant in gastrointestinal malignancies, which infrequently respond to immunotherapy. Although we clearly need more accurate biomarkers to predict response to immune checkpoint inhibition in gas...
Source: Clinical Advances in Hematology and Oncology - March 9, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Pediatric Langerhans cell histiocytosis: state of the science and future directions.
Authors: Thacker NH, Abla O Abstract Langerhans cell histiocytosis (LCH) is an inflammatory neoplasm of myeloid origin characterized by the presence of classic CD1a+/CD207+ cells. An ongoing debate over the grouping of LCH was finally settled in favor of neoplasm after the discovery of the BRAF V600E mutation in 2010. The pathologic cells were found to involve an almost universal activation of the MAPK/ERK pathway, with mutations identified in most kinases upstream of ERK (RAS/RAF/MEK). The clinical presentation of LCH is a mixed bag, ranging from self-resolving localized disease to fulminant, fatal disseminated di...
Source: Clinical Advances in Hematology and Oncology - March 9, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Insights into lymphoma from the 2018 American Society of Clinical Oncology annual meeting.
Authors: PMID: 30807556 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - February 27, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Insights into lymphoma from the 2018 American Society of Clinical Oncology annual meeting: commentary.
Authors: Andorsky DJ PMID: 30807557 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - February 27, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Therapeutic advances in metastatic pancreatic adenocarcinoma and related cancers: focus on evidence-based and sequenced approaches to survival extension in metastatic pancreatic adenocarcinoma.
Authors: Bekaii-Saab T, Yu K, Lima CMSR, Wolin EM PMID: 30807558 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - February 27, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Translating landmark trial-based evidence to the front lines of care for pancreatic cancer: the evolving trial-based and guideline-supported role for nanoliposomal topoisomerase inhibitors in metastatic pancreatic adenocarcinoma.
Authors: Lima CMSR PMID: 30807559 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - February 27, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

A treatment landscape in evolution: new strategies, guidelines, and therapeutic advances for metastatic pancreatic adenocarcinoma.
Authors: Bekaii-Saab T PMID: 30807560 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - February 27, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

New guideline-sanctioned and emerging interventions for pancreatic cancer.
Authors: Bekaii-Saab T PMID: 30807561 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - February 27, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Identifying ideal candidates for nanoliposomal topoisomerase inhibitors in metastatic pancreatic adenocarcinoma.
Authors: Yu K PMID: 30807562 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - February 27, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Real-world approaches for extending progression-free survival in patients with metastatic pancreatic neuroendocrine tumors: focus on timing, sequencing, regimen initiation, and maintenance strategies using somatostatin analogs, targeted agents, and peptide receptor radiotherapy.
Authors: Wolin EM PMID: 30807563 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - February 27, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in renal cell carcinoma from the seventeenth International Kidney Cancer Symposium.
Authors: PMID: 30807564 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - February 27, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

How I treat metastatic colorectal cancer.
Authors: Bekaii-Saab T PMID: 30807565 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - February 27, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Highlights in colorectal cancer from the 2018 American Society of Clinical Oncology annual meeting.
Authors: PMID: 30807566 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - February 27, 2019 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Hem/Onc News.
Authors: Schuyler D PMID: 30543584 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - December 15, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

New paradigms and therapies for iron replacement in iron deficiency anemia.
Authors: Auerbach M PMID: 30543585 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - December 15, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The role of HER2 amplification testing in metastatic colorectal cancer.
Authors: Raghav KPS PMID: 30543586 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - December 15, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

The role of the NCI Investigational Drug Branch.
Authors: Moscow J PMID: 30543587 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - December 15, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Loncastuximab tesirine in patients with B-cell non-Hodgkin lymphoma.
Authors: Kahl BS PMID: 30543588 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - December 15, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Microsatellite instability in colorectal cancer: overview of its clinical significance and novel perspectives.
This article, an overview of the expanding role of MSI in CRC, covers its clinical significance, the available data on molecular profiling, novel perspectives on MSI testing, biomarkers in MSI-H CRC, immunotherapy resistance, and novel immunotherapy strategies. PMID: 30543589 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - December 15, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Novel therapeutic approaches in polycythemia vera.
Authors: Foucar CE, Stein BL Abstract Polycythemia vera (PV) is the most common Philadelphia chromosome-negative myeloproliferative neoplasm. Whereas low-risk patients are treated with aspirin and phlebotomy, high-risk patients receive cytoreductive therapy, which most commonly consists of hydroxyurea in the United States. Concerns about the long-term safety of hydroxyurea, as well as a desire for more efficacious and targeted therapy, have led to the development of novel therapies for high-risk patients with PV. Pegylated interferon (IFN) has shown promise in phase 2 studies of PV, and preliminary data from ongoin...
Source: Clinical Advances in Hematology and Oncology - December 15, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Growing my practice, keeping up with medical knowledge, and handling adverse outcomes.
Authors: Ramalingam S PMID: 30543591 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - December 15, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Hem/Onc News.
Authors: Schuyler D PMID: 30543592 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - December 15, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Ethical issues in the development of oncology drugs.
Authors: Kimmelman J PMID: 30543593 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - December 15, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Management of epithelial ovarian cancer.
Authors: Leitao MM PMID: 30543594 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - December 15, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Tisagenlecleucel in pediatric patients with acute lymphoblastic leukemia.
Authors: Maude SL PMID: 30543595 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - December 15, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

A closer look at regorafenib.
Authors: Bekaii-Saab T PMID: 30543596 [PubMed - in process] (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - December 15, 2018 Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research